Generic Name and Formulations:
Anthralin 1%; crm, contains salicylic and ascorbic acid.
Indications for DRITHO-CREME:
Quiescent or chronic psoriasis.
Initially apply once daily (5–10 minutes contact time) for at least one week; may increase contact time to 20–30 minutes before washing off. Treat until skin is entirely clear. Individualize. For skin: use sparingly. For scalp: wash and rinse hair.
Acute psoriatic eruptions.
Renal disease. Avoid eyes, mucous membranes, folds and creases of the skin. Apply cautiously on intertriginous skin areas. Restrict application to psoriatic lesions. Discontinue if sensitization or excessive irritation develops. May stain fabrics; avoid. Pregnancy (Cat.C). Nursing mothers.
Possible contact allergic reactions, severe irritation, discolored hair or fingernails.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds